眾生藥業(002317.SZ)複方血栓通膠囊、腦栓通膠囊等產品入選國家醫保目錄
格隆匯8月21日丨眾生藥業(002317.SZ)公佈,2019年8月20日,根據《國家醫保局人力資源社會保障部關於印發的通知》,公司、公司全資子公司廣東華南藥業集團有限公司、公司全資子公司廣東先強藥業有限公司及控股子公司廣東逸舒製藥股份有限公司(以下簡稱“逸舒製藥”)共有249個產品品規入選《國家基本醫療保險、工傷保險和生育保險藥品目錄》(以下簡稱“《醫保目錄2019年版》”),其中甲類147個,乙類102個。公司的核心產品複方血栓通膠囊(獨家)、腦栓通膠囊(獨家)和潛力品種硫糖鋁口服混懸液、羧甲司坦口服溶液、鹽酸氮斯汀滴眼液、普拉洛芬滴眼液等繼續入選本次目錄;公司眼科產品明目地黃膠囊(獨家)以及複方血栓通滴丸新進《醫保目錄2019版》;羧甲司坦片、維生素B6片、格列齊特片由醫保目錄乙類調整為醫保目錄甲類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.